☆ 4.6 Meeting Abstract

First-In-Human Phase 1/2 Trial of Anti-AXL Antibody-Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC

JOURNAL OF THORACIC ONCOLOGY (2019)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 14, Issue 10, Pages S209-S209

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2019.08.414

Keywords

advanced NSCLC; Antibody-drug conjugate; Enapotamab vedotin

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.